Latest Sanofi Stories
ALBANY, N.Y., July 1, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris
- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today
MONTREAL, June 30, 2014 /CNW Telbec/ - For more than 75 youngsters with life-threatening allergies, participating in a soccer clinic hosted by the Montreal Impact and Allerject(TM) was a dream
ALBANY, N.Y., June 23, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study
-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions -- BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ --
SCRS Welcomes INC Research, inVentiv Health, Novartis and Sanofi ELLICOTT CITY, Md., June 13, 2014 /PRNewswire/ -- Leading sponsor and CRO organizations continue to join the Society
DALLAS, June 13, 2014 /PRNewswire/ -- MarketReportsChina.com adds "Research on China Cardiovascular Drugs Industry, 2014-2018" market intelligence report of 85 pages to
Both doses of investigational drug sarilumab met all three co-primary endpoints PARIS and TARRYTOWN, N.Y., June 12, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY)
SAN FRANCISCO, June 11, 2014 /PRNewswire/ -- Kindred Biosciences, Inc.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.